Shots: This BLA is for the treatment of RA, PsA, AS, CD, UC, chronic psoriasis, HS, and JIA The clinical study included (PK/PD) and Ph III trials in ankylosing spondylitis showing its safety, efficacy and quality Bio-Thera is developing 7 biosimilars including BAT1406, with Avastin biosimilar currently being assessed in a global Ph III […]Read More
Shots: Collaboration is focused on using Regeneron’s Velocisuite platform for the discovery and characterization of human antibodies, T cell receptors and bluebird will contribute in gene transfer and cell therapy The program has six initial targets with additional targets may be selected in five year term 50/50 R&D cost sharing till IND application. Regeneron has […]Read More
Shots: Agreement involves the two oral pan-Akt kinase inhibitors afuresertib (ASB183) and uprosertib (UPB795) with >10 clinical Ph1/2 tested for cancer Accordingly, Novartis will acquire equity stake in Laenka adding upfront fees and milestones including royalties A second agreement b/w them in addition CFG920(CYP17 inhibitor) licensing, an oral androgen inhibitor, for prostate cancer Click here […]Read More
Shots: With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety To identify specific subgroups population to develop targeted treatments GSK is initially planning to leverage 23andMe databases for the development of its LRRK2i molecule in preclinical stage targeting Parkinson’s Click here to read full press release/ article […]Read More
Shots: The approval is based on non-inferiority data demonstrating biosimilarity between Nivestym and the reference product, Neupogen (filgrastim) Pfizer has received the US FDA’s fourth approvals for its biosimilar including Nivestym and will be available at a discount of wholesale acquisition cost (WAC) of Neupogen Nivestym (filgrastim-aafi, Neupogen) is a mAb, indicated to decrease the […]Read More
Shots: The approval is based on non-inferiority data demonstrating biosimilarity between Retacrit and the reference product, Epogen & Procrit In May, 2016 Pfizer and Vifor Pharma collaborated for the commercialization of retacrit in certain therapeutic areas Retacrit (epoetin alfa) a biosimilar to Epogen & Procrit, is an erythropoiesis-stimulating agent (ESA) indicated for anemia and reduction […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
